Category: by publisher

Update on the Gressner case: Son Olav says he’s the unfairly targeted “bête noire”

We have an update on the case of Olav and Axel Gressner, a father-son (or, in this case, son-father) pair of German liver researchers caught up in a fraud investigation. The inquiry focused on Olav, who left the University of Aachen under a cloud of suspicion. A 2008 research letter on which he was a co-author (his father was senior author) was retracted earlier this year by the Journal of Hepatology.

The journal’s position in the retraction notice,  published online in June and in print in September, bears repeating here. The authors: Continue reading Update on the Gressner case: Son Olav says he’s the unfairly targeted “bête noire”

Academic purgatory: Papers withdrawn before they’re “officially” published

If a paper appears online but then is withdrawn — a kinder, gentler version of retracted — before it is “officially” published, did anyone hear it fall?

Oops, mixed metaphors again. And scare quotes! The latter, however, are because publishers seem to have varying opinions of whether or not something that is freely available online is published. And that has ramifications for whether you can retract a paper like that.

Let us explain with two examples: Continue reading Academic purgatory: Papers withdrawn before they’re “officially” published

After misrepresentation allegations, German anesthesiologist Joachim Boldt out as hospital’s chief physician

Ludwigshafen Hospital, via Wikimedia http://commons.wikimedia.org/wiki/File:Klinikum_Ludwigshafen_Nordseite.jpg

Joachim Boldt, a leading German anesthesiologist who had a 2009 paper in Anesthesia & Analgesia retracted last month* amid allegations  that he had misrepresented parts of the study, has been relieved of his duties as chief physician at Ludwigshafen Hospital.

A press release from the German Society for Anesthesiology and Intensive Care Medicine (DGAI) condemns Boldt’s actions. The press release goes on (translated from German): Continue reading After misrepresentation allegations, German anesthesiologist Joachim Boldt out as hospital’s chief physician

Duke’s Anil Potti resigns

Duke University photo

Duke’s Anil Potti, the Duke cancer researcher who falsely claimed to be a Rhodes Scholar and may have faked several analyses of chemotherapy and cancer, has resigned from the university.

The Duke Chronicle reports that Potti

…stepped down from his position at Duke’s Institute for Genome Sciences and Policy Friday and took responsibility for the problems in his research, IGSP Director Huntington Willard wrote in an e-mail to IGSP staff.

Willard wrote that Potti “accepted full responsibility for a series of anomalies in data handling, analysis and management that have come under scrutiny in the past months.”

He said that investigations into Potti’s research will continue, as will IGSP’s examinations of Potti’s science.

The resignation follows the retraction earlier this week of one paper Potti co-authored in the Journal of Clinical Oncology.

We’ll update as we learn more.

Please see an update about a second paper now being retracted by one of Potti’s co-authors.

More on the latest Cell retraction: PI says a graduate student was at fault

Carsten Carlberg

This morning we reported on a new retraction in Cell involving fraud from a lab in Finland, which led us to a second retraction of a paper by the same group in the Journal of Molecular Biology. The first author on both papers was Tatjana Degenhardt, who at the time was a graduate student in the lab of Carsten Carlberg, professor of biochemistry at the University of Kuopio.

A few minutes ago Retraction Watch spoke with Carlberg, who had this to say about Degenhardt: Continue reading More on the latest Cell retraction: PI says a graduate student was at fault

More on Ahluwalia et al Nature retraction, from Tom DeCoursey

Yesterday,we posted on the retraction of a 2004 Nature paper on innate immunity whose findings had been questioned by two groups. A few hours after we posted that item, we heard back from the senior author of one of the papers doubting that data, Tom DeCoursey. DeCoursey makes a number of important points, so we thought it would be a good idea to share them as a post: Continue reading More on Ahluwalia et al Nature retraction, from Tom DeCoursey

Previously questioned Nature paper on innate immunity retracted

courtesy Nature

Last week, we noted a Nature editorial in which the journal came clean about its higher-than-average number of retractions this year — four. What we missed was the fact that the fourth retraction of the year also appeared in last week’s issue.

The retraction, of a paper called “The large-conductance Ca2+-activated K+ channel is essential for innate immunity,” reads (link to the author’s homepage added): Continue reading Previously questioned Nature paper on innate immunity retracted

Third retraction for Indiana University scientist who altered figures in NIH-funded research

Another shoe has dropped in the case of Emily M. Horvath, the Indiana researcher whose tinkering with figures while on a $369,000 federal grant ended in sanctions by government officials.

Biochemical and Biophysical Research Communications, an Elsevier title, has retracted another paper on which Horvath was an author, bringing to three the number of her articles tainted in the scandal. The paper, “A novel membrane-based anti-diabetic action of atorvastatin,” was published online in June 2008, and cited four times since, according to Thomson Scientific’s Web of Knowledge. (Atorvastatin is sold as Lipitor.) According to the journal: Continue reading Third retraction for Indiana University scientist who altered figures in NIH-funded research

Update on Axel Ullrich retractions: Lead author manipulated figures, says Ullrich

Axel Ullrich, courtesy the Max Planck Institute

Yesterday, we noted that Axel Ullrich, a decorated cancer researcher, had retracted two papers in the Journal of Biological Chemistry. The journal gave no explanation for the retractions, and our conversation with the publication director for the American Society for Biochemistry and Molecular Biology, which puts out the journal, was less than illuminating. This morning, Ullrich responded to all of the questions we sent him by email, and our follow-ups. The picture is now a lot more clear.

Ullrich tells Retraction Watch that he found out from a “private investigator” several months ago that the papers’ lead author, Naohito Aoki, had manipulated their figures. Aoki was a postdoc in Ullrich’s lab in the early 1990s: Continue reading Update on Axel Ullrich retractions: Lead author manipulated figures, says Ullrich

Scientist raised serious questions about 2008 Cell study by Amy Wagers

Amy Wagers, a Harvard stem cell researcher, retracted a Nature study last week and has another published paper under scrutiny at Blood. Retraction Watch has now learned that a 2008 Cell paper she co-authored drew significant criticism from a stem cell researcher at Children’s National Medical Center.

In the paper, Wagers and her team said they were able to prepare a set of muscle cells that reversed some of the effects of muscular dystrophy in a mouse model of the disease. In a 2008 letter to the editor of Cell, however, Terence Partridge wrote Continue reading Scientist raised serious questions about 2008 Cell study by Amy Wagers